CV SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0376 USD | -5.16% |
|
-5.28% | +6.50% |
| Mar. 28 | Transcript : CV Sciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024 | |
| Mar. 28 | CV Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 412.4 | 95.82 | 47.1 | 13.04 | 4.945 | 5.465 |
| Enterprise Value (EV) 1 | 400.1 | 96.95 | 50.85 | 12.58 | 5.862 | 4.59 |
| P/E ratio | 47.9 x | -5.68 x | -2.11 x | -0.81 x | -0.44 x | 1.77 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 8.55 x | 1.78 x | 1.93 x | 0.65 x | 0.31 x | 0.34 x |
| EV / Revenue | 8.29 x | 1.81 x | 2.08 x | 0.63 x | 0.36 x | 0.29 x |
| EV / EBITDA | 37.2 x | -17.9 x | -2.34 x | -1.03 x | -1.27 x | 1.19 x |
| EV / FCF | 110 x | 10.8 x | -50.9 x | -6.34 x | -32.5 x | 10.4 x |
| FCF Yield | 0.91% | 9.25% | -1.97% | -15.8% | -3.07% | 9.57% |
| Price to Book | 13.6 x | 3.29 x | 4.22 x | 3.7 x | -6.34 x | 1.97 x |
| Nbr of stocks (in thousands) | 95,675 | 99,297 | 100,203 | 111,796 | 152,635 | 154,605 |
| Reference price 2 | 4.310 | 0.9650 | 0.4700 | 0.1166 | 0.0324 | 0.0354 |
| Announcement Date | 3/12/19 | 3/30/20 | 3/19/21 | 4/4/22 | 3/30/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 48.24 | 53.7 | 24.43 | 20.05 | 16.2 | 16 |
| EBITDA 1 | 10.77 | -5.408 | -21.72 | -12.26 | -4.621 | 3.846 |
| EBIT 1 | 10.25 | -6.124 | -22.59 | -13.41 | -5.613 | 3.611 |
| Operating Margin | 21.24% | -11.4% | -92.48% | -66.9% | -34.64% | 22.56% |
| Earnings before Tax (EBT) 1 | 10.09 | -17.22 | -22.6 | -15.64 | -9.181 | 3.096 |
| Net income 1 | 10 | -16.61 | -22.28 | -15.55 | -9.134 | 3.102 |
| Net margin | 20.73% | -30.93% | -91.22% | -77.58% | -56.37% | 19.38% |
| EPS 2 | 0.0900 | -0.1700 | -0.2230 | -0.1443 | -0.0728 | 0.0200 |
| Free Cash Flow 1 | 3.654 | 8.968 | -0.9996 | -1.986 | -0.1802 | 0.4394 |
| FCF margin | 7.57% | 16.7% | -4.09% | -9.9% | -1.11% | 2.75% |
| FCF Conversion (EBITDA) | 33.94% | - | - | - | - | 11.42% |
| FCF Conversion (Net income) | 36.53% | - | - | - | - | 14.16% |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/12/19 | 3/30/20 | 3/19/21 | 4/4/22 | 3/30/23 | 3/29/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|
| Net sales | 5.107 | 4.969 | 4.447 | 4.138 | - |
| EBITDA | -2.735 | -2.568 | -2.475 | -1.826 | - |
| EBIT | -2.98 | -8.843 | -1.515 | -2.315 | - |
| Operating Margin | -58.35% | -177.96% | -34.07% | -55.94% | - |
| Earnings before Tax (EBT) | -0.04 | -8.955 | -2.217 | -2.651 | - |
| Net income 1 | -0.04 | -8.857 | -2.217 | -3.573 | -1.031 |
| Net margin | -0.78% | -178.25% | -49.85% | -86.35% | - |
| EPS 2 | - | -0.0800 | -0.0200 | -0.0300 | -0.0100 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 8/15/22 | 11/14/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 1.13 | 3.75 | - | 0.92 | - |
| Net Cash position 1 | 12.2 | - | - | 0.45 | - | 0.88 |
| Leverage (Debt/EBITDA) | - | -0.2095 x | -0.1727 x | - | -0.1984 x | - |
| Free Cash Flow 1 | 3.65 | 8.97 | -1 | -1.99 | -0.18 | 0.44 |
| ROE (net income / shareholders' equity) | 43% | -56.1% | -110% | -211% | -660% | 292% |
| ROA (Net income/ Total Assets) | 21.5% | -8.54% | -33.9% | -34.4% | -22.8% | 20.6% |
| Assets 1 | 46.54 | 194.4 | 65.74 | 45.17 | 40.1 | 15.08 |
| Book Value Per Share 2 | 0.3200 | 0.2900 | 0.1100 | 0.0300 | -0.0100 | 0.0200 |
| Cash Flow per Share 2 | 0.1300 | 0.0900 | 0.0400 | 0.0100 | 0 | 0.0100 |
| Capex 1 | 0.89 | 1.12 | 1.06 | 0.04 | - | - |
| Capex / Sales | 1.85% | 2.08% | 4.33% | 0.17% | - | - |
| Announcement Date | 3/12/19 | 3/30/20 | 3/19/21 | 4/4/22 | 3/30/23 | 3/29/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +6.50% | 6.15M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- CVSI Stock
- Financials CV Sciences, Inc.
